ICD-10-CM 2026 · Effective October 1, 2025

ICD-10 D47.3

Billable / Specific HCC v28: 48

Essential (hemorrhagic) thrombocythemia

D47
Block
3
Synonyms
1,297
LCDs
43
Payer Policies
38
Linked CPTs

About ICD-10-CM D47.3

ICD-10-CM code D47.3 represents Essential (hemorrhagic) thrombocythemia. This is a billable/specific code in the Neoplasms chapter (block D47). The 2026 edition of ICD-10-CM D47.3 became effective on October 1, 2025.

Coding Tips for D47.3

Specialist guidance from the PayerReady Medical Coding Team. Specificity warnings, HCC capture rules, sequencing notes.

HCC capture: document with MEAT each year

D47.3 is a CMS-HCC v28 risk-adjustment code (category 48). To count for the patient Risk Adjustment Factor (RAF), document the diagnosis with MEAT language each calendar year: Monitored, Evaluated, Assessed, Treated. A diagnosis on the problem list alone does not satisfy CMS RADV audit standards. Include the diagnosis in the assessment with current status and current treatment plan.

Inclusion Terms / Approximate Synonyms

Clinical terms and conditions classified under D47.3. Per CMS ICD-10-CM Tabular 2026.

  • Essential thrombocytosis
  • Idiopathic hemorrhagic thrombocythemia
  • Primary thrombocytosis

Type 2 Excludes

Not included here, the excluded code is not part of D47.3, but a patient may have both conditions at the same time. Both codes may be coded together when applicable.

  • reactive thrombocytosis (D75.838)
  • secondary thrombocytosis (D75.838)
  • thrombocythemia NOS (D75.839)
  • thrombocytosis NOS (D75.839)

Medicare Advantage HCC Impact

CMS-HCC v28 (current)
Category 48
ESRD-HCC
Category 48
RxHCC (Part D)
Category 48

Capture this diagnosis annually for accurate risk adjustment. Missed HCC captures are the #1 revenue leak in Medicare Advantage risk programs.

Medicare LCD Coverage for D47.3

Local Coverage Determinations (LCDs) from CMS MACs that list D47.3 as a covered diagnosis.

1,297 LCDs

Showing top 10 of 1,297 total . Click a CPT for full coverage scope.

CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81215 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81300 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81351 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81167 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81405 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 0103U →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81201 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81297 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81298 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81299 →

Commercial Payer Coverage

Coverage policies from major commercial payers referencing D47.3.

43 policies

1 Cigna

Flow Cytometry - (0538)
Policy ID: MM_0538

5 Medicare

Oral Anticancer Drugs - Policy Article
Policy ID: ART-52479
Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article
Policy ID: ART-52480
Billing and Coding: Biomarkers for Oncology
Policy ID: ART-52986
Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
Policy ID: ART-55639
Billing and Coding: Lab: Flow Cytometry
Policy ID: ART-55717

CPT Codes Commonly Billed with D47.3

Procedures frequently paired with this diagnosis based on PayerReady's Dx↔Px linkage data.

38 linkages
  • J0840 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J0850 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • 90371 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • 90375 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1573 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1569 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1459 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1557 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1556 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1560 CMS LCD: Billing and Coding: Immune Globulins CMS LCD

Convert D47.3 to ICD-9-CM

Per CMS General Equivalence Mappings (GEMs), useful for legacy data review and historical claim analysis.

ICD-10ICD-9Mapping Flags
D47.3 23871 10000

Flags format (5 digits): Approximate · No Map · Combination · Scenario · Choice List. Source: CMS 2017 GEMs (final version).

ICD-10 D47.3, Billing FAQ

Is ICD-10 code D47.3 billable? +

Yes, D47.3 is a billable ICD-10-CM code that can appear as a primary or secondary diagnosis on claims.

What other names or terms map to D47.3? +

ICD-10 D47.3 includes: Essential thrombocytosis; Idiopathic hemorrhagic thrombocythemia; Primary thrombocytosis.

What codes are Type 2 Excludes for D47.3? +

Type 2 Excludes (may be coded together when both conditions exist): reactive thrombocytosis (D75.838); secondary thrombocytosis (D75.838); thrombocythemia NOS (D75.839)

Does D47.3 affect Medicare Advantage HCC risk adjustment? +

Yes. D47.3 maps to CMS-HCC v28 category 48. Capture this diagnosis annually for accurate Medicare Advantage risk score.

What CPT codes are commonly billed with D47.3? +

Procedures frequently paired with D47.3 include: J0840, J0850, 90371, 90375, J1573.

What ICD-9 codes does D47.3 map to? +

Per CMS GEMs, D47.3 maps to ICD-9 codes: 23871. Useful for legacy data review and historical claim analysis.

Get the full PayerReady toolkit

Free access to CPT/ICD-10 lookup, denial appeals, fee comparator, and claim auditing with credentialing enrollment.

Start free →

Run this code through our claim audit tool

Check NCCI bundling, MUE limits, and modifier logic before submission.

Try the auditor →

Did this page help?

Quick signal so we know what to improve.

Thanks!

If you want a code reference page that doesn't exist yet, email coding@payerready.com.

Sorry to hear that.

Tell us what's missing or wrong: coding@payerready.com. We respond within 5 business days.

Reviewed by the PayerReady Medical Coding Team

Verified against the CMS 2026 code set on May 31, 2026.

Powered by 11K CPT · 98K ICD-10 · 860K MPFS rates · 4.5M NCCI edits · 9.5M NPIs. Our data methodology · About our coding team

Faster Approvals

Ready to Cut Your Enrollment Timeline in Half?

Join providers in all 50 states who handed off credentialing to a dedicated specialist. Create your free account in minutes and start enrolling the same day.

All 50 States Covered
No Long-Term Contracts
HIPAA HIPAA Compliant Platform
Dedicated Specialist Included